Cervical cancer, geographical inequalities, prevention and barriers in resource depleted countries (Review)
- Authors:
- Anna Bogdanova
- Charles Andrawos
- Constantina Constantinou
-
Affiliations: Department of Basic and Clinical Sciences, University of Nicosia Medical School, CY‑1700 Nicosia, Republic of Cyprus - Published online on: February 9, 2022 https://doi.org/10.3892/ol.2022.13233
- Article Number: 113
-
Copyright: © Bogdanova et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
|
Globocan 2020, . New Global Cancer Data. Uicc.org. 2021.https://www.uicc.org/news/globocan-2020-new-global-cancer-dataSeptember 18–2021 | |
|
Al Jishi T and Sergi C: Current perspective of diethylstilbestrol (DES) exposure in mothers and offspring. Reprod Toxicol. 71:71–77. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Adcock R, Cuzick J, Hunt WC, McDonald RM and Wheeler CM; New Mexico HPV Pap Registry Steering Committee, : Role of HPV genotype, multiple infections, and viral load on the risk of high-grade cervical Neoplasia. Cancer Epidemiol Biomarkers Prev. 28:1816–1824. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Doorbar J, Egawa N, Griffin H, Kranjec C and Murakami I: Human papillomavirus molecular biology and disease association. Rev Med Virol. 25 (Suppl):S2–S23. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Galloway D and Laimins L: Human papillomaviruses: Shared and distinct pathways for pathogenesis. Cur Opin Virol. 14:87–92. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Plummer M, de Martel C, Vignat J, Ferlay J, Bray F and Franceschi S: Global burden of cancers attributable to infections in 2012: A synthetic analysis. Lancet Glob Health. 4:e609–e616. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Wagner M, Bennetts L, Patel H, Welner S, de Sanjose S and Weiss T: Global availability of data on HPV genotype-distribution in cervical, vulvar and vaginal disease and genotype-specific prevalence and incidence of HPV infection in females. Infect Agent Cancer. 10:132015. View Article : Google Scholar : PubMed/NCBI | |
|
Yuan Y, Cai X, Shen F and Ma F: HPV post-infection microenvironment and cervical cancer. Cancer Lett. 497:243–254. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Cohen O, Schejter E, Agizim R, Schonman R, Chodick G, Fishman A and Hershko Klement A: Postcoital bleeding is a predictor for cervical dysplasia. PLoS One. 14:e02173962019. View Article : Google Scholar : PubMed/NCBI | |
|
Reed N, Balega J, Barwick T, Buckley L, Burton K, Eminowicz G, Forrest J, Ganesan R, Harrand R, Holland C, et al: British Gynaecological Cancer Society (BGCS) cervical cancer guidelines: Recommendations for practice. Eur J Obstet Gynecol Reprod Biol. 256:433–465. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Issa Z, Aloan H and Al Niyazee A: Accuracy of Pap smear in cervical cancer screening. World Family Med J. 17:16–20. 2019. View Article : Google Scholar | |
|
Johnson CA, James D, Marzan A and Armaos M: Cervical cancer: An overview of pathophysiology and management. Semin Oncol Nurs. 35:166–174. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Pkhakadze G, Bokhua Z, Asatiani T, Muzashvili T and Burkadze G: Evaluation of the risk of cervical intraepithelial neoplasia progression based on cell proliferation index, epithelial-mesenchymal transition and co-infections. Georgian Med News. 178–184. 2020.PubMed/NCBI | |
|
Bhatla N, Aoki D, Sharma DN and Sankaranarayanan R: Cancer of the cervix Uteri. Int J Gynaecol Obstet. 143:22–36. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Li X, Xia L, Chen X, Fu Y and Wu X: Simple conization and pelvic lymphadenectomy in early-stage cervical cancer: A retrospective analysis and review of the literature. Gynecol Oncol. 158:231–235. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Landoni F, Maneo A, Zapardiel I, Zanagnolo V and Mangioni C: Class I versus class III radical hysterectomy in stage IB1-IIA cervical cancer. A prospective randomized study. Eur J Surg Oncol. 38:203–209. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Gopalani SV, Janitz AE and Campbell JE: Cervical cancer incidence and mortality among Non-Hispanic African American and white women, United States, 1999–2015. J Natl Med Assoc. 112:632–638. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Lott BE, Trejo MJ, Baum C, McClelland DJ, Adsul P, Madhivanan P, Carvajal S, Ernst K and Ehiri J: Interventions to increase uptake of cervical screening in Sub-Saharan Africa: A scoping review using the Integrated Behavioral Model. BMC Public Health. 20:6542020. View Article : Google Scholar : PubMed/NCBI | |
|
International agency for research on cancer, . Cervix uteri fact sheet. 2020.https://gco.iarc.fr/today/data/factsheets/cancers/23-Cervix-uteri-fact-sheet.pdfOctober 28–2021 | |
|
Aylward J Global burden of cervical cancer, . In TogetHER for Health. 2021.https://togetherforhealth.org/global-burden-cervical-cancer/November 28–2021 | |
|
Keenan M: Human Development Index (HDI). Salem Press Encyclopedia. 2021.https://search.ebscohost.com/login.aspx?direct=true&AuthType=ip,sso&db=ers&AN=98402115&site=eds-liveSeptember 28–2021 | |
|
Arbyn M, Weiderpass E, Bruni L, de Sanjosé S, Saraiya M, Ferlay J and Bray F: Estimates of incidence and mortality of cervical cancer in 2018: A worldwide analysis. Lancet Glob Health. 8:e191–e203. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Burton-Jeangros C, Cullati S, Manor O, Courvoisier DS, Bouchardy C and Guessous I: Cervical cancer screening in Switzerland: Cross-sectional trends (1992–2012) in Social Inequalities. Eur J Public Health. 27:167–173. 2017.PubMed/NCBI | |
|
Lam JO, Lim WY, Chow KY and D'Souza G: Incidence, trends and ethnic differences of oropharyngeal, anal and cervical cancers: Singapore, 1968–2012. PLoS One. 10:e01461852015. View Article : Google Scholar : PubMed/NCBI | |
|
Garau M, Musetti C, Alonso R and Barrios E: Trends in cancer incidence in Uruguay: 2002–2015. Colomb Med (Cali). 50:224–238. 2019.PubMed/NCBI | |
|
Gopalani S, Janitz A and Campbell J: Cervical Cancer Incidence and Mortality among Non-Hispanic African American and White Women, United States, 1999–2015. J Natl Med Assoc. 112:632–638. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Lott B, Trejo M, Baum C, McClelland D, Adsul P, Madhivanan P, Carvajal S, Ernst K and Ehiri J: Interventions to increase uptake of cervical screening in sub-Saharan Africa: A scoping review using the integrated behavioral model. BMC Public Health. 20:6542020. View Article : Google Scholar : PubMed/NCBI | |
|
Lekoane K, Kuupiel D, Mashamba-Thompson T and Ginindza T: Evidence on the prevalence, incidence, mortality and trends of human papilloma virus-associated cancers in Sub-Saharan Africa: Systematic scoping review. BMC Cancer. 19:5632019. View Article : Google Scholar : PubMed/NCBI | |
|
Kisling LA: Prevention strategies. StatPearls. 2021.https://www.ncbi.nlm.nih.gov/books/NBK537222/September 15–2021 | |
|
Von Karsa L, Arbyn M, De Vuyst H, Dillner J, Dillner L, Franceschi S, Patnick J, Ronco G, Segnan N, Suonio E, et al: European guidelines for quality assurance in cervical cancer screening. Summary of the supplements on HPV screening and vaccination. Papillomavirus Res. 1:22–31. 2015. View Article : Google Scholar | |
|
Banday A, Jeelani S and Hruby V: Cancer vaccine adjuvants-recent clinical progress and future perspectives. Immunopharmacol Immunotoxicol. 37:1–11. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Bogani G, Leone Roberti Maggiore U, Signorelli M, Martinelli F, Ditto A, Sabatucci I, Mosca L, Lorusso D and Raspagliesi F: The role of human papillomavirus vaccines in cervical cancer: Prevention and treatment. Crit Rev Oncol Hematol. 122:92–97. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Bosch F, Robles C, Díaz M, Arbyn M, Baussano I, Clavel C, Ronco G, Dillner J, Lehtinen M, Petry K, et al: HPV-FASTER: Broadening the scope for prevention of HPV-related cancer. Nat Rev Clin Oncol. 13:119–132. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Cuzick J and Wheeler C: Need for expanded HPV genotyping for cervical screening. Papillomavirus Res. 2:112–115. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Bruni L, Saura-Lázaro A, Montoliu A, Brotons M, Alemany L, Diallo MS, Afsar OZ, Lamontagne DS, Mosina L, Contreras M, et al: HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010–2019. Prev Med. 144:1063992021. View Article : Google Scholar : PubMed/NCBI | |
|
Siu J, Fung T and Leung L: Social and cultural construction processes involved in HPV vaccine hesitancy among Chinese women: A qualitative study. Int J Equity Health. 18:1472019. View Article : Google Scholar : PubMed/NCBI | |
|
Termrungruanglert W, Khemapech N, Vasuratna A, Havanond P, Deebukkham P, Kulkarni A and Pavelyev A: The epidemiologic and economic impact of a quadrivalent human papillomavirus vaccine in Thailand. PLoS One. 16:e02458942021. View Article : Google Scholar : PubMed/NCBI | |
|
Daley E, Vamos C, Zimet G, Rosberger Z, Thompson E and Merrell L: The Feminization of HPV: Reversing gender biases in US Human papillomavirus vaccine policy. Am J Public Health. 106:983–984. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Daley E, Vamos C, Thompson E, Zimet G, Rosberger Z, Merrell L and Kline N: The feminization of HPV: How science, politics, economics and gender norms shaped U.S. HPV vaccine implementation. Papillomavirus Res. 3:142–148. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Patel C, Brotherton J, Pillsbury A, Jayasinghe S, Donovan B, Macartney K and Marshall H: The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: What additional disease burden will a nonavalent vaccine prevent? Euro Surveill. 23:17007372018. View Article : Google Scholar : PubMed/NCBI | |
|
Chidyaonga-Maseko F, Chirwa M and Muula A: Underutilization of cervical cancer prevention services in low and middle income countries: A review of contributing factors. Pan Afr Med J. 21:2312015. View Article : Google Scholar : PubMed/NCBI | |
|
Jaiswal J, LoSchiavo C, Maiolatesi A, Kapadia F and Halkitis P: Misinformation, Gendered perceptions, and low healthcare provider communication around HPV and the HPV vaccine among young sexual minority Men in New York City: The P18 cohort study. J Community Health. 45:702–711. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Morris M, Friedemann Smith C, Boxell E, Wardle J, Simon A and Waller J: Quantitative evaluation of an information leaflet to increase prompt help-seeking for gynaecological cancer symptoms. BMC Public Health. 16:3742016. View Article : Google Scholar : PubMed/NCBI | |
|
Okan Y, Petrova D, Smith S, Lesic V and Bruine de Bruin W: How do Women interpret the NHS information leaflet about cervical cancer screening? Med Decis Making. 39:738–754. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Kolthoff S, Hestbech M, Jørgensen K and Brodersen J: Do invitations for cervical screening provide sufficient information to enable informed choice? A cross-sectional study of invitations for publicly funded cervical screening. J R Soc Med. 109:274–281. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Ngu S, Wei N, Kwan T, Chu M, Tse K, Chan K and Ngan H: Impact of different educational interventions on psychosocial well-being of women with a positive high-risk human papillomavirus and normal cervical cytology: A randomised trial. J Psychosom Obstet Gynaecol. 39:146–155. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Calderón-Mora J, Byrd TL, Alomari A, Salaiz R, Dwivedi A, Mallawaarachchi I and Shokar N: Group versus individual culturally tailored and theory-based education to promote cervical cancer screening among the underserved Hispanics: A cluster randomized trial. Am J Health Promot. 34:15–24. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Clavé Llavall A, de Wildt G, Meza G, Tattsbridge J and Jones L: Nurses' and teachers' perceived barriers and facilitators to the uptake of the human papilloma virus (HPV) vaccination program in Iquitos, Peru: A qualitative study. PLoS One. 16:e02552182021. View Article : Google Scholar : PubMed/NCBI | |
|
Catarino R, Petignat P, Dongui G and Vassilakos P: Cervical cancer screening in developing countries at a crossroad: Emerging technologies and policy choices. World J Clin Oncol. 6:281–290. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Tranberg M, Bech B, Blaakær J, Jensen J, Svanholm H and Andersen B: Preventing cervical cancer using HPV self-sampling: Direct mailing of test-kits increases screening participation more than timely opt-in procedures-a randomized controlled trial. BMC Cancer. 18:2732018. View Article : Google Scholar : PubMed/NCBI | |
|
Maver P and Poljak M: Primary HPV-based cervical cancer screening in Europe: Implementation status, challenges, and future plans. Clin Microbiol Infect. 26:579–583. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Woronoff A, Molinié F and Trétarre B: Implementation of national cervical cancer screening program in France. Bull Cancer. 106:253–261. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
De Prez V, Jolidon V, Willems B, Cullati S, Burton-Jeangros C and Bracke P: Cervical cancer (over)screening in Belgium and Switzerland: Trends and social inequalities. Eur J Public Health. 30:410–415. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Watson M, Benard V and Flagg E: Assessment of trends in cervical cancer screening rates using healthcare claims data: United States, 2003–2014. Prev Med Rep. 9:124–130. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Landy R, Sasieni PD, Mathews C, Wiggins CL, Robertson M, McDonald YJ, Goldberg DW, Scarinci IC, Cuzick J and Wheeler CM; New Mexico HPV Pap Registry Steering Committee, : Impact of screening on cervical cancer incidence: A population-based case-control study in the United States. Int J Cancer. 147:887–896. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Landy R, Mathews C, Robertson M, Wiggins CL, Mcdonald YJ, Goldberg DW, Scarinci IC, Cuzick J, Sasieni PD and Wheeler CM: A state-wide population-based evaluation of cervical cancers arising during opportunistic screening in the United States. Gynecol Oncol. 159:344–353. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Sankaranarayanan R, Nene B, Shastri S, Jayant K, Muwonge R, Budukh AM, Hingmire S, Malvi SG, Thorat R, Kothari A, et al: HPV screening for cervical cancer in rural India. N Engl J Med. 360:1385–1394. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Dorji T, Tshomo U, Gyamtsho S, Tamang S, Wangmo S and Pongpirul K: Gender-neutral HPV elimination, cervical cancer screening, and treatment: Experience from Bhutan. Int J Gynaecol Obstet. Apr 30–2021.(Epubs ahead of print). doi: 10.1002/ijgo.13728. PubMed/NCBI | |
|
Kim JJ, Campos NG, Sy S, Burger EA, Cuzick J, Castle PE, Hunt WC, Waxman A and Wheeler CM; New Mexico HPV Pap Registry Steering Committee, : Inefficiencies and High-value improvements in U.S. Cervical cancer screening practice. Ann Internal Med. 163:589–597. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Singh U, Anjum, Qureshi S, Negi N, Singh N, Goel M and Srivastava K: Comparative study between liquid-based cytology & conventional Pap smear for cytological follow up of treated patients of cancer cervix. Indian J Med Res. 147:263–267. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Karimi-Zarchi M, Peighmbari F, Karimi N, Rohi M and Chiti Z: A Comparison of 3 ways of conventional pap smear, liquid-based cytology and colposcopy vs cervical biopsy for early diagnosis of premalignant lesions or cervical cancer in women with abnormal conventional pap test. Int J Biomed Sci. 4:205–210. 2013.PubMed/NCBI | |
|
Ramírez-Palacios P, Chen A, Flores YN, Crespi CM, Lazcano-Ponce E, Alvarez-Escobedo D, Torres-Ibarra L, Rivera-Paredez B, León-Maldonado L, Hernández-López R, et al: Benefit of double-reading cytology smears as a triage strategy among high-risk human papillomavirus-positive women in Mexico. Cancer Cytopathol. 128:715–724. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Lee H, Kang Y and Ju W: Cervical cancer screening in developing countries: Using visual inspection methods. Clin J Oncol Nurs. 20:79–83. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Orang'o E, Wachira J, Asirwa F, Busakhala N, Naanyu V, Kisuya J, Otieno G, Keter A, Mwangi A and Inui T: Factors associated with uptake of visual inspection with acetic Acid (VIA) for cervical cancer screening in western Kenya. PLoS One. 11:e01572172016. View Article : Google Scholar : PubMed/NCBI | |
|
Kudva V, Prasad K and Guruvare S: Andriod device-based cervical cancer screening for resource-poor settings. J Digital Imaging. 31:646–654. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Koliopoulos G, Nyaga V, Santesso N, Bryant A, Martin-Hirsch P, Mustafa R, Schünemann H, Paraskevaidis E and Arbyn M: Cytology versus HPV testing for cervical cancer screening in the general population. Cochrane Database Syst Rev. 8:CD0085872017.PubMed/NCBI | |
|
Arbyn M, Simon M, Peeters E, Xu L, Meijer CJLM, Berkhof J, Cuschieri K, Bonde J, Ostrbenk Vanlencak A, Zhao F, et al: 2020 list of human papillomavirus assays suitable for primary cervical cancer screening. Clin Microbiol Infect. 27:1083–1095. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Ronco G, Dillner J, Elfström KM, Tunesi S, Snijders PJ, Arbyn M, Kitchener H, Segnan N, Gilham C, Giorgi-Rossi P, et al: Efficacy of HPV-based screening for prevention of invasive cervical cancer: Follow-up of four European randomised controlled trials. Lancet. 383:524–532. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Castle PE, Pierz AJ, Adcock R, Aslam S, Basu P, Belinson J, Cuzick J, El-Zein M, Ferreccio C, Firnhaber C, et al: A pooled analysis to compare the clinical characteristics of human papillomavirus-positive and -negative cervical precancers. Cancer Prev Res. 13:829–840. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Reid JL, Wright TC, Stoler MH, Cuzick J, Castle PE, Dockter J, Getman D and Giachetti C: Human papillomavirus oncogenic mRNA testing for cervical cancer screening. Am J Clin Pathol. 144:473–483. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Cuzick J, Cadman L, Ahmad AS, Ho L, Terry G, Kleeman M, Lyons D, Austin J, Stoler MH, Vibat CRT, et al: Performance and diagnostic accuracy of a urine-based human papillomavirus assay in a referral population. Cancer Epidemiol Biomarkers Prev. 26:1053–1059. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Torres-Ibarra L, Lazcano-Ponce E, Franco EL, Cuzick J, Hernandez-Avila M, Lorincz A, Rivera B, Ramírez P, Mendiola-Pastrana I, Rudolph S, et al: Triage strategies in cervical cancer detection in Mexico: Methods of the FRIDA study. Salud Publica Mex. 58:197–210. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Torres-Ibarra L, Cuzick J, Lorincz AT, Spiegelman D, Lazcano-Ponce E, Franco E, Moscicki A, Mahmud S, Wheeler C, Rivera-Paredez B, et al: Comparison of HPV-16 and HPV-18 genotyping and cytological testing as triage testing within human papillomavirus-based screening in Mexico. JAMA Netw Open. 2:e19157812019. View Article : Google Scholar : PubMed/NCBI | |
|
Cuzick J, Du R, Adcock R, Kinney W, Joste N, McDonald R, English K, Torres S, Saslow D and Wheeler C; New Mexico HPV Pap Registry Steering Committee, : Uptake of co-testing with HPV and cytology for cervical screening: A population-based evaluation in the United States. Gynecol Oncol. 162:555–559. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Kyrgiou M, Arbyn M, Bergeron C, Bosch F, Dillner J, Jit M, Kim J, Poljak M, Nieminen P, Sasieni P, et al: Cervical screening: ESGO-EFC position paper of the European Society of Gynaecologic Oncology (ESGO) and the European Federation of Colposcopy (EFC). Br J Cancer. 123:510–517. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Castle PE, Adcock R, Cuzick J, Wentzensen N, Torrez-Martinez N, Torres S, Stoler M, Ronnett B, Joste N, Darragh T, et al: Relationships of p16 immunohistochemistry and other biomarkers with diagnoses of cervical abnormalities: Implications for LAST terminology. Arch Pathol Lab Med. 144:725–734. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Macedo AC, Gonçalves JC, Bavaresco DV, Grande AJ, Chiaramonte Silva N and Rosa MI: Accuracy of mRNA HPV tests for triage of precursor lesions and cervical cancer: A systematic review and meta-analysis. J Oncol. 2019:69350302019. View Article : Google Scholar : PubMed/NCBI | |
|
Shah UJ, Nasiruddin M, Dar SA, Khan MK, Akhter MR, Singh N, Rabaan AA and Haque S: Emerging biomarkers and clinical significance of HPV genotyping in prevention and management of Cervical Cancer. Microb Pathog. 143:1041312020. View Article : Google Scholar : PubMed/NCBI | |
|
van Leeuwen RW, Oštrbenk A, Poljak M, van der Zee AG, Schuuring E and Wisman GB: DNA methylation markers as a triage test for identification of cervical lesions in a high risk human papillomavirus positive screening cohort. Int J Cancer. 144:746–754. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Tian Y, Yuan Wu NY, Liou YL, Yeh CT, Cao L, Kang YN, Wang HJ, Li Y, Chu TY, Li W, et al: Utility of gene methylation analysis, cytological examination, and HPV-16/18 genotyping in triage of high-risk human papilloma virus-positive women. Oncotarget. 8:62274–62285. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Banila C, Lorincz AT, Scibior-Bentkowska D, Clifford GM, Kumbi B, Beyene D, Wheeler CM, Cuschieri K, Cuzick J and Nedjai B: Clinical performance of methylation as a biomarker for cervical carcinoma in situ and cancer diagnosis: A worldwide study. Int J Cancer. 150:290–302. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Cook DA, Krajden M, Brentnall AR, Krajden M, Gondara L, Chan T, Law J, Smith L, Niekerk D, Ogilvie G, et al: Evaluation of a validated methylation triage signature for human papillomavirus positive women in the HPV FOCAL cervical cancer screening trial. Int J Cancer. 144:2587–2595. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Louvanto K, Franco EL, Ramanakumar AV, Vasiljević N, Scibior-Bentkowska D, Koushik A, Cuzick J, Coutlée F and Lorincz AT; Biomarkers of Cervical Cancer Risk Study Team, : Methylation of viral and host genes and severity of cervical lesions associated with human papillomavirus type 16. Int J Cancer. 136:E638–E645. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Vale D, Teixeira J, Bragança J, Derchain S, Sarian L and Zeferino L: Elimination of cervical cancer in low- and middle-income countries: Inequality of access and fragile healthcare systems. Int J Gynecol Obstet. 152:7–11. 2020. View Article : Google Scholar | |
|
Ngwalle EW, Mgaya HN, Mpanju-Shumbusho W, Chirenje ZM, Kirumbi L, Lebelle T and Kaggwa S: Situation analysis for diagnosis and treatment of cervical cancer in mainland Tanzania. East Afr Med J. 78:60–64. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Rosser JI, Hamisi S, Njoroge B and Huchko MJ: Barriers to cervical cancer screening in rural Kenya: Perspectives from a provider survey. J Community Health. 40:756–761. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
McDonald YJ, Goldberg DW, Scarinci IC, Castle PE, Cuzick J, Robertson M and Wheeler CM: Health Service Accessibility and risk in cervical cancer prevention: Comparing rural versus nonrural residence in New Mexico. J Rural Health. 33:382–392. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Bingham A, Bishop A, Coffey P, Winkler J, Bradley J, Dzuba I and Agurto I: Factors affecting utilization of cervical cancer prevention services in low-resource settings. Salud Publica Mex. 45 (Suppl 3):S408–S416. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Markovic M, Kesic V, Topic L and Matejic B: Barriers to cervical cancer screening: A qualitative study with women in Serbia. Soc Sci Med. 61:2528–2535. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Urasa M and Darj E: Knowledge of cervical cancer and screening practices of nurses at a regional hospital in Tanzania. Afr Health Sci. 11:48–57. 2011.PubMed/NCBI |
